Waters Corporation filed an 8-K on November 3, 2026, reporting third-quarter 2026 financial results, raising full-year 2026 guidance across every component, and announcing the acquisition of MOBILion Systems, Inc.

Key Highlights

  • Total Q3 2026 reported revenue: $1.767 billion, exceeding guidance midpoint by $14 million, according to the filing.
  • Adjusted EPS grew 21%: to $4.10 for Q3 2026, compared to $3.40 for Q3 2025; GAAP diluted EPS was $0.82.
  • Organic revenue: $871 million in Q3 2026 versus $800 million in Q3 2025, representing growth of 9% as reported and 10% in constant currency.
  • Full-year 2026 total reported revenue guidance: raised to a range of $6.479 billion to $6.497 billion, a $43 million increase at the midpoint.
  • MOBILion Systems acquired: the company disclosed it acquired MOBILion Systems, Inc., described as "the pioneer of SLIM high-resolution ion mobility separation technology."
  • Full-year 2026 adjusted EPS guidance: updated to $14.60 to $14.70, representing 11% to 12% year-over-year growth.
  • 2027 growth framework: management disclosed it would outline reshoring, synergies, and AI-related demand drivers on its earnings conference call.

Waters Corporation Reports Q3 2026 Divisional Performance and Raises Annual Outlook

Waters Corporation (NYSE:WAT), which operates across four divisions following its acquisition of the Biosciences and Diagnostic Solutions businesses from Becton, Dickinson and Company, reported segment-level results for the third quarter ended September 30, 2026. The Analytical Sciences Division (ASD), described in the filing as the former Waters Division excluding the Clinical Business Unit, delivered reported revenue of $703 million in the quarter, compared to $649 million in Q3 2025, led by what the filing characterized as double-digit instrument and chemistry growth. The Materials Sciences Division, formerly the TA Division, contributed $93 million in revenue, up from $87 million a year earlier.

The Biosciences Division (WBD), formerly BD Biosciences, reported revenue of $396 million versus $387 million in the prior year comparable period. Within the Advanced Diagnostics Division (ADx), the Diagnostic Solutions business generated $500 million compared to $498 million in the prior year comparable period, while the Clinical Business Unit contributed $75 million versus $64 million in Q3 2025. The filing noted that prior year figures for the acquired businesses reflect results "as they were historically managed by BDX" and "do not necessarily reflect what these businesses' results of operations would have been had they operated as a part of Waters during the period presented."

For the fourth quarter of 2026, the company expects total reported revenue of $1.801 billion to $1.819 billion, with organic constant currency growth of 7.0% to 9.0% and acquired business reported revenue of approximately $817 million. Fourth quarter adjusted EPS is guided to $4.58 to $4.68, representing 1% to 3% year-over-year growth. The filing also stated that the MOBILion acquisition "is expected to broaden the Company's entry into the proteomics market," complementing Waters' mass spectrometry portfolio, though the financial terms of that transaction were not detailed in this filing.

What Was Disclosed

Waters Corporation disclosed Q3 2026 financial results, raised all components of its full-year 2026 guidance including a $43 million revenue increase at the midpoint, and announced the completed acquisition of MOBILion Systems, Inc., a developer of high-resolution ion mobility separation technology.